The all-cash buyout, which gives AbbVie access to Capstan Therapeutics’ in vivo edited CAR T therapy for B cell–mediated autoimmune diseases, adds to a growing sense of momentum in M&A, according to BMO Capital Markets.
AbbVie Plunks Down $2.1B for Capstan and Its Novel CAR T Therapies Read More »
The agency said it issued the import alerts because it “continues to have concerns related to outstanding Quality System regulation violations by Olympus.”
Patrick Conway, who recently became chief executive of the larger Optum health services division, will replace Dr. Amar Desai as CEO of Optum Health.
UnitedHealth changes leadership at care delivery unit Read More »
Digging into a prespecified analysis for the mid-stage study, INmune Bio identified some clinical and biological benefits of its TNF inhibitor in patients with early Alzheimer’s disease who have at least two biomarkers of inflammation.
INmune Crashes After Missing Cognitive Target in Phase II Alzheimer’s Trial Read More »
The rise of monoclonal antibodies brought back hope for stalling or reversing the devastating neurodegenerative disease. Big Pharma has taken notice with a handful of high-value deals, GlobalData reports.
Alzheimer’s Deals Surged 780% After Leqembi, Kisunla Broke Approval Stalemate Read More »
BMS is letting go of 68 employees in Lawrenceville, New Jersey. The pharma has now cut over 1,000 employees there since April 2024 as part of its cost-cutting measures.
BMS Continues New Jersey Layoffs, Bringing Yearly Total to Nearly 900 Read More »
In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the company pulled its application for a combo flu/COVID-19 shot, saying it would refile following data from this Phase III trial.
Moderna’s Promised mRNA Flu Vaccine Bests Current Standard Shot Read More »
In an open letter addressing the Trump administration’s proposed budget cuts to HHS, the executives urged Congress to continue “robust federal funding” for scientific research, which they say will help maintain U.S. biotech leadership globally.
100+ CEOs, Biopharma Leaders Sound Alarm on ‘Catastrophic’ Health Cuts Read More »
As of Apr. 22, Sage had 338 full-time employees, all of whom will be laid off effective Aug. 22. The layoffs were announced a few weeks after Maryland’s Supernus Pharmaceuticals acquired Sage for up to $795 million.
Unos científicos han desarrollado una familia de compuestos capaces de mejorar el tratamiento de diversas enfermedades metabólicas. El trabajo lo ha realizado un equipo integrado por personal investigador de la Universidad de Valencia (UV) y del Instituto de Investigació …
Nueva familia de compuestos para tratar enfermedades metabólicas Read More »
